# Eli Lilly's $1500 Target Surprises Wall Street

> Eli Lilly's revenue growth outpaces stock price, with analysts missing a $1500 target by 2027
- Title: Eli Lilly's $1500 Target Surprises Wall Street · 24/7 Wall St.
- Summary: Eli Lilly's revenue growth outpaces stock price, with analysts missing a $1500 target by 2027 Eli Lilly could reach $1500 per share by 2027 if retatrutide…
- Keywords: eli lilly, mounjaro, zepbound, retatrutide, fda approval, novo nordisk, forward p/e, revenue growth, stock price, analyst targets, investor expectations, cardiovascular risk
- Source: 24/7 Wall St. — https://247wallst.com/investing/2026/09/21/the-next-chapter-of-eli-lilly-could-be-bigger-than-investors-expect
- Author: Vandita Jadeja
- Published: 2026-09-21T17:30:17+00:00
- Read time: 1 min
- Topics: eli lilly, mounjaro, zepbound, retatrutide, fda approval, novo nordisk, forward p/e, revenue growth, stock price, analyst targets, investor expectations, cardiovascular risk
## Revenue Growth vs Stock Price
Eli Lilly reports 48% year-over-year revenue growth while shares trade nearly flat year to date.
## 48% Revenue Growth
Mounjaro and Zepbound generated $14.9 billion in Q2 revenue, with CEO David Ricks stating Lilly's future has never been brighter.

> Lilly's future, after 150 years, has never been brighter
## Stock Stalls Despite Growth
Shares dropped 9.95% in the past month after climbing 3.34% in the last week, despite strong revenue growth.
## Analyst Targets
Wall Street targets $1,325.39 for Eli Lilly, implying 15% upside from current prices, but the author believes $1,500 is achievable.
## Path to $1500
Reaching $1,500 requires a 30.1% gain from current prices, with key catalysts including FDA approvals for cardiovascular risk and breast cancer treatments.
## Regulatory Risks
The primary risk is a regulatory delay on retatrutide's biologic classification, which could compress stock price gains instead of expanding them.
## Key takeaway

Eli Lilly could reach $1500 per share by 2027 if retatrutide clears regulatory hurdles and prescriber adoption grows